On April 10-11, 2024, BioCon China Expo 2024, the 11th International Biomedical Technology Exhibition, was successfully held in Beijing. This conference brought together numerous industry leaders such as the National Development and Reform Commission, well-known pharmaceutical companies at home and abroad, and investment institutions to jointly explore cutting-edge topics in biomedicine.

　　The two-day event gathered over 20 in-depth sub forums, including the "High Level Forum," "Self Exemption Drug Innovation and Development," and "BD Investment and Financing New Trends Forum," aimed at focusing on core issues in the field of biomedicine and conducting in-depth discussions.

　　As a representative of the biopharmaceutical industry, Dr. Li Ziqiang from Weidejie Biotechnology gave a special report at the "Innovation and Development of Self Exempted Drugs" sub forum, discussing with authoritative experts and business leaders the cutting-edge innovation trends of self exempt biopharmaceuticals, and jointly promoting the full speed development of innovative biopharmaceuticals.

　　At the 11th International Biomedical Technology Exhibition, the final selection results of each award at BioCon Awards 2024 were announced. The six major awards cover upstream and downstream enterprises/organizations/individuals in the biopharmaceutical industry chain, building an authoritative industry award that covers the entire industry cycle, selecting annual leaders in each link, commending industry pioneers, and creating a positive and innovative industry atmosphere and environment for the biopharmaceutical industry to move forward.

　　Beijing Weidejie Biotechnology Co., Ltd. has won the "Top 10 Innovative Enterprises with Annual Investment Value" award, which recognizes the emerging biotechnology enterprises with the most market potential and investment value in the industry in 2023.

      The award of "Annual Investment Value Innovation Enterprise" is not only an encouragement and recognition from the industry for Weidejie Biotechnology, but also a confident expectation for the company's future development. The company will continue to deepen its cultivation in the field of innovative drugs for autoimmune diseases, rare diseases, and actively promote RA, iMCD, CRS, irAE/oncology UC、pSS、SLE、ALS、 The study of indications for gouty arthritis and other conditions provides patients with more and better treatment options.

　　Regarding the BioCon Awards:

　　The BioCon Awards is an authoritative biopharmaceutical award created by the BioCon China Expo organizing committee. Thanks to the ten years of accumulation of the BioCon brand, the "BioCon Awards" gather authoritative experts in the industry to form a professional evaluation team, and select representatives of pioneering enterprises/organizations/individuals from various fields of the biotechnology industry from multiple dimensions, fairness, and impartiality. The aim is to encourage enterprises/organizations/individuals in the biopharmaceutical industry chain to continuously forge ahead, explore and innovate, establish a new industry model guided by clinical value and driven by technological innovation, and promote the continuous progress of the biopharmaceutical industry.

　　Regarding Weidejie:

　　Beijing VDJBio Co., LTD. is a national high-tech enterprise registered in Haidian District, Beijing, and a specialized and innovative small and medium-sized enterprise in Beijing. Focusing on innovative antibody drug development in the field of autoimmune diseases. With a unique antibody discovery and optimization platform, a complete platform for small, medium, and industrial production of large molecule drugs, a series of antibody/fusion protein drugs with the best potential for treating autoimmune diseases have been developed.